Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
41 studies found for:    " February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" February 18, 2009":" March 20, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated
Has Results
Minocycline for HIV+ Cognitive Impairment in Uganda
Conditions: HIV-associated Cognitive Impairment;   HIV Infections
Interventions: Drug: minocycline;   Drug: minocycline placebo capsule
2 Recruiting A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir/Ritonavir, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Conditions: HIV;   HIV Infections;   Pregnancy
Interventions: Drug: TMC114 (darunavir);   Drug: ritonavir;   Drug: TMC125 (etravirine);   Drug: TMC278 (rilpivirine)
3 Completed A Trial to Evaluate Ad35-GRIN/ENV HIV Vaccine in Healthy Adult Volunteers
Conditions: HIV;   HIV Infections
Interventions: Biological: Ad35-GRIN/ENV;   Biological: Ad35-GRIN
4 Unknown  Evaluating Post-test HIV Counseling Videos for Teens
Conditions: HIV;   HIV Infections
Intervention: Behavioral: Video
5 Completed
Has Results
Effects of Contingency Management for Methamphetamine Abstinence on Post-Exposure Prophylaxis for HIV in Men Who Have Sex With Men (MSM)
Conditions: Amphetamine-Related Disorders;   HIV;   HIV Infections
Interventions: Drug: Truvada;   Behavioral: CM
6 Completed Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)
Conditions: HIV;   HIV Infections
Interventions: Biological: V526;   Biological: Comparator: Placebo to V526
7 Active, not recruiting Effect of Diet-induced Weight Loss on HIV-associated Metabolic Syndrome
Conditions: HIV (Human Immunodeficiency Virus);   Metabolic Syndrome;   HIV Infections
Intervention: Behavioral: Dietary Intervention
8 Completed Training Community Members to Deliver HIV Prevention Programs to Urban Youth
Conditions: HIV;   HIV Infections
Interventions: Behavioral: Be Proud! Be Responsible!;   Behavioral: Becoming A Responsible Teen (BART);   Behavioral: Reducing the Risk
9 Withdrawn Raltegravir Activity In Lymphoid Tissues
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: Efavirenz + Tenofovir DF/Emtricitabine;   Drug: Raltegravir + Tenofovir DF/Emtricitabine;   Procedure: Colonoscopy with biopsies;   Procedure: Inguinal Lymph Node Excision
10 Completed
Has Results
Buprenorphine/Raltegravir Pharmacokinetic Interaction Study
Conditions: HIV Infection;   HIV Infections
Intervention: Drug: Raltegravir
11 Completed Study to Evaluate HIV Viremia and Persistence in Acutely HIV-Infected ARV Naïve Patients Treated With Darunavir/Ritonavir and Etravirine
Conditions: Acute HIV Infection;   HIV Infections
Intervention: Drug: Darunavir/Ritonavir and Etravirine
12 Completed The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
Conditions: HIV Positive;   Opioid Dependence;   Opioid Agonist Treatment;   HIV Infections
Intervention:
13 Withdrawn Pharmacotherapy for HIV Infected Patients With Alcohol Problems
Conditions: HIV Infection;   Heavy Alcoholic Consumption;   HIV Infections
Intervention: Drug: Naltrexone
14 Recruiting Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals?
Conditions: HIV Infection;   Herpes Simplex Type II;   HIV Infections
Interventions: Drug: valacyclovir;   Drug: Placebo
15 Completed
Has Results
A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
Conditions: HIV-1;   HIV Infections
Interventions: Other: Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine;   Biological: Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose);   Biological: Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose);   Biological: Comparator: Placebo to MRKAd5 HIV-1 gag vaccine
16 Completed A Worldwide, Phase I, Dose-Escalating Study of a 3-Dose Regimen of the MRKAd5 (Clade B) Vaccine in Healthy Adults (V520-018)
Conditions: HIV-1;   HIV Infections
Interventions: Biological: V520;   Biological: Comparator: V520 (1x10^9 vp/d);   Biological: Comparator: V520 (1x10^10 vp/d);   Biological: Comparator: Placebo
17 Completed Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue
Conditions: HIV/AIDS;   HIV Infections
Interventions: Drug: darunavir;   Drug: Ritonavir;   Drug: Etravirine
18 Completed Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
Conditions: HIV Infection;   HIV Infections
Interventions: Drug: AZT+3TC+ABV (Trizivir);   Drug: Switching to LPV/r monotherapy (Kaletra)
19 Completed Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r
Conditions: HIV/HCV Co-infection;   HIV Infections
Interventions: Drug: Lopinavir/ritonavir;   Drug: Lopinavir/ritonavir with two nucleoside analogs
20 Active, not recruiting Strategic Timing of Antiretroviral Treatment
Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years